Key facts
- This page summarizes Benjamin R. Yerxa's Form 4 filing for Clearside Biomedical, Inc. (CLSD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 May 2024, 17:28.
Benjamin R. Yerxa - 15 May 2024 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)
- Reporting relationship
- Director
- Issuer ticker
- CLSD
- Reported as of
- 15 May 2024
- Net transaction value
- +$10,235
- SEC form
- 4
- Accepted by SEC
- 15 May 2024, 17:28:42 UTC
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 21 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Benjamin R. Yerxa filed Form 4 for Clearside Biomedical, Inc. (CLSD) on 15 May 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: +$10,235.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLSD
transaction
Common Stock
Purchase
- Transaction value
- $10,235
- Shares
- +7,813
- Change %
- +77%
- Price
- $1.31
- Shares after
- 17,957
- Date
- 15 May 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.